Ling Fu

TL;DR: A 26-year-old man with metastatic medulloblastoma that was refractory to multiple therapies was treated with a novel hedgehog pathway inhibitor, GDC-0449; treatment resulted in rapid (although transient) regression of the tumor and reduction of symptoms.

TL;DR: This article showed that although ligand-dependent activation of the hedgehog signalling pathway has been associated with tumorigenesis in a number of human tissues, Hh ligands failed to activate signalling in tumour epithelial cells.

TL;DR: It is reported that FGF19 transgenic mice had a significant and specific reduction in fat mass that resulted from an increase in energy expenditure and did not become obese or diabetic on a high fat diet.

TL;DR: Examination of expression of the epithelial marker E-cadherin by immunohistochemistry on primary tumor samples from subjects enrolled in a randomized NSCLC clinical trial in which erlotinib in combination with chemotherapy previously failed to show clinical activity supports a potential role for EMT as a determinant of EGFR activity in NSCLCs tumor cells.

TL;DR: Treatment with FGF19 prevented or reversed the diabetes that develops in mice made obese by genetic ablation of brown adipose tissue or genetic absence of leptin, and profiled the F GF19-induced gene expression changes in the liver and brown fat.